The previous page is sending you to https://news.bms.com/news/details/2015/Bristol-Myers-Squibb-and-AbbVie-Receive-FDA-Approval-of-Empliciti-elotuzumab-for-the-Treatment-of-Patients-with-Multiple-Myeloma-Who-Have-Received-One-to-Three-Prior-Therapies/default.aspx.

 If you do not want to visit that page, you can return to the previous page.